MSTN and sarcopenia: Therefore, there is an urgent need to develop potential treatment options, including an ammonia-lowering approach that blocks the myostatin–activin receptor pathway, as well as hormonal therapy, regenerative therapeutics, and their combinations, to prevent and reverse sarcopenia.